In the context of the joint project GANI_MED (Greifswald Approach to Individualized Medicine) certain disease phenotypes and biomarker candidates are to be identified with the help of association studies. Thus, GANI_MED aims at contributing to the establishment of routines, improving the implementation of PPPM in the clinical area. A unique characteristic of GANI_MED is the integration of bioethics, history of medicine and health economics throughout the project. The volume starts with a definition of the term "Individualized Medicine" (IM) which is resilient in terms of academic science studies. This will be followed by a chapter that focuses on the socio-cultural backgrounds of IM from the perspective of history of medicine. It will show that IM is also deeply rooted in broader societal developments: the endeavor to extract more and more socio-biological health information from populations in order to detect risk factors and to get a valid data base for conceptualizing efficient curative and preventive interventions on an individual and population-based level. The next chapter will provide deeper insights into medical-analytical research in the framework of GANI_MED: metabolome-related biomarker research, non-pharmaceutical interventions (the example of immunoadsorption) and pharmacogenetics. Chapter 5 will deal with conceptualethical questions and critiques of IM and wants to prove to what extent these critiques are justifiable. It also deals with the primary question of IM: do individual risks, that can be detected, play a role for the demand for personal and joint responsibility in a health care system which is shaped by solidarity. A subchapter will deal with the question to what extend IM will face social resistance if its promises of healing can only be formulated against the task of a good, free and self-determined life in general. Beside conceptual questions, also application-orientated problems with regard to research ethics of IM have been investigated within GANI_MED. This includes the Informed Consent architecture which was developed for the question, how participants can be included into such clinical-epidemiological studies as well as considerations about the frequency and processing of incidental findings. The concluding chapter will focus on the questions related to the evaluation of health economics: IM has the potential to alter the rules, institutions and regulations of the health care sector. However, there are major barriers preventing the keystakeholders to adopt this new approach to medicine. Based on reliable methods of health economic evaluation the relation between the effectiveness of some PPPMbased therapies and the corresponding costs are calculated. This ratio can be regarded as a guiding criterion for decision makers in the health care system for allocating scare resources. The conclusion of the volume will be a chapter in which the most important results from historical, ethical and health-economical single-case study will be summed up.
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